Pharmacyclics oncology
Executive Summary
Former Bristol-Myers Squibb VP-Oncology Global Marketing Timothy Whitten joins Pharmacyclics Sept. 4 as senior VP-marketing and sales. Whitten will initially head marketing of company's Phase III brain metastases compound Xcytrin (motexafin gadolinium). Pharmacyclics hopes to file the Xcytrin NDA in the first half of 2002